ATTO Insider Trading Activity and SEC Form 4 Filings
ATTO insider trading summary
Over the past 12 months, insiders at Attovia Therapeutics, Inc. (ATTO) reported 414 sales worth $40.5M by 9 insiders and 44 open-market purchases worth $227.3M by 14 insiders on SEC Form 4. Net insider buying was $186.8M.
Latest ATTO insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Aug 6, 2026 | Goldman Sachs Group Inc | Insider | Buy | $8.5M (500,000 @ $17.00) |
| Aug 6, 2026 | Jeremy Green | 10% Owner | Buy | $3.4M (200,000 @ $17.00) |
| Aug 6, 2026 | Redmile Group, LLC | 10% Owner | Buy | $3.4M (200,000 @ $17.00) |
| Aug 6, 2026 | Sanofi | Insider | Buy | $5.1M (300,000 @ $17.00) |
| Aug 6, 2026 | Jeremy Green | 10% Owner | Buy | $6.8M (400,000 @ $17.00) |
| Aug 6, 2026 | Redmile Biopharma Investments III, L.P. | 10% Owner | Buy | $6.8M (400,000 @ $17.00) |
| Aug 6, 2026 | venBio Global Strategic Fund IV, L.P. | Insider | Buy | $6.5M (382,352 @ $17.00) |
| Aug 6, 2026 | Redmile Biopharma Investments III, L.P. | 10% Owner | Buy | $3.4M (200,000 @ $17.00) |
| Aug 6, 2026 | Redmile Group, LLC | 10% Owner | Buy | $6.8M (400,000 @ $17.00) |
| Aug 6, 2026 | Goldman Sachs & Co. LLC | Insider | Buy | $8.5M (500,000 @ $17.00) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.